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- 
Neuropsychiatric side effects often complicate anti-Parkinsonian therapy and pose a 
significant problem in the optimal management of idiopathic Parkinson’s disease. Several 
publications report a relative lack of neuropsychiatric side effects in Parkinsonian patients 
treated with subcutaneous apomorphine. To investigate this further, we have used 
subcutaneous apomorphine to treat 12 non-demented IPD patients with previous oral 
drug-related neuropsychiatric problems. 
Treatment with apomorphine allowed alteration of anti-Parkinsonian medication and led 
to the abolition or reduction of neuropsychiatric complications in all patients. The 
mechanism remains unclear but may be due, in part, to a reduction in oral medication or a 
psychotropic action of apomorphine, possibly due to the piperidine moiety in its structure, or 
both. 0 1997 Elsevier Science Ltd 
Parkinson’s disease Neuropsychiatric Apomorphine 
INTRODUCTION 
Levodopa, apomorphine and dopamine agonist ergot 
derivatives, such as lisuride and pergolide, differ in 
their anti-Parkinsonian effects, pharmacokinetics and 
side effect profile. The use of apomorphine, with 
achievement of steady state plasma drug levels, results 
in stable control of the symptoms of Parkinson’s 
disease in chronically levodopa treated patients with 
frequent and disabling dose-related motor response 
fluctuations [l]. In advanced Parkinson’s disease 
levodopa related motor response fluctuations may be 
associated with variable psychomotor responses. In 
addition to these on-off fluctuations, one third of 
subjects with advanced Parkinson’s disease show a 
wide range of neuropsychiatric side effects including 
visual hallucinosis, paranoid behaviour, changes in 
awareness and depression [2]. These factors may be 
related to progressive pathology or the development 
of cortical Lewy body disease, but also to the use of 
levodopa. 
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The use of different oral dopamine agonists can 
result in the achievement of an improved clinical 
profile in individual subjects, although neuro- 
psychiatric side effects of drugs, such as lisuride or 
bromocriptine, may complicate an otherwise accept- 
able control of Parkinsonism. Apomorphine, con- 
sidered to be the most potent dopamine receptor 
agonist, has been shown to be unable to activate 
schizophrenic symptoms or induce psychosis in non- 
schizophrenics [3]. Furthermore, Tamminga et nl. [4] 
have reported an improvement in psychotic features 
in neuroleptic-responsive schizophrenics treated with 
apomorphine, although this remains contraversial. 
Recent studies using subcutaneous apomorphine to 
treat refractory on-off oscillations in Parkinson’s 
disease have also reported a relative paucity of 
neuropsychiatric complications, though no formal 
studies have been undertaken [5,6]. We have been 
using subcutaneous apomorphine for over 8 years 
and have been impressed by the relative lack of 
neuropsychiatric complications in PD patients with 
on-off oscillations treated with subcutaneous 
apomorphine and optimisation of oral therapy. We 
report here our experience in an open study of the use 
of apomorphine in Parkinson’s disease patients with 
severe and varied neuropsychiatric complications on 
oral therapy. 
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PATIENTS AND METHODS 
Patients 
Subjects included in this study had probable 
idiopathic Parkinson’s Disease, satisfying the UK 
Brain Bank criteria and had severe neuropsychiatric 
complications on oral anti-Parkinsonian medication, 
some requiring hospital admission for levodopa 
induced psychosis (n = 2) and hallucinations (n = 3) 
[7]. Prior to apomorphine therapy all subjects had 
formal neuropsychiatric evaluation using the 
mentation, behaviour and mood section of the Unified 
Parkinson’s Disease Rating Scale (UPDRS) and assess- 
ment of performance and verbal IQ using a structured 
interview [8]. Neuropsychiatric evaluation at off stage 
was not possible because of severe bradyphrenia, 
bradykinesia and rigidity. Off period neuropsychiatric 
complications included screaming (n = 2) and hallu- 
cinations and paranoia (n = 2). Neuropsychiatric 
complications required reduction of levodopa and 
oral dopamine agonists in all patients prior to 
commencing apomorphine and two patients with 
severe levodopa intolerance remained off levodopa 
at the expense of worsening control of the Parkin- 
sonian movement disorder. All subjects had severe 
motor response fluctuations related to chronic L-dopa 
therapy and were treated with apomorphine over a 
mean period of 28 months, from 1989 to 1995. During 
this time, 12 non-demented IPD patients (mean age ? 
SD 59 _’ 14 y, range 39-78; duration of IPD 11 t 6 y, 
range 3-23) specifically selected for intolerance to oral 
therapy because of neuropsychiatric complications 
were treated with apomorphine. The patient details 
are shown in Table 1. 
Reasons for the introduction of apomorphine were 
as follows: 
a: Neuropsychiatric complications when increas- 
ing anti-Parkinsonian medication, particularly 
visual hallucinations and agitation/manic 
episodes. 
b: Severe motor response fluctuations, often with 
unpredictable off periods. 
c: Severe L-dopa induced dyskinesias. 
The exact treatment prior to apomorphine therapy 
and whilst on apomorphine is shown in Table 2. 
Prior to treatment with subcutaneous apomorphine, 
the L-dopa dosage was 704.2 + 497 g (mean % SD). 
Nine patients took oral dopamine agonists. Manipula- 
tions with oral therapy proved unsuccessful in 
reducing the neuropsychiatric complications prior to 
the commencement of apomorphine therapy. Ten of 
the patients had neuropsychiatric symptoms on their 
medications before apomorphine was started and two 
of the patients developed symptoms as oral therapy 
was increased to control motor fluctuations and 
therefore could not tolerate the increase in medication. 
One patient, intolerant to L-dopa and oral dopamine 
agonists due to neuropsychiatric side effects, remains 
on apomorphine alone. At the time of writing, the 
mean duration of treatment with apomorphine is 
28 months (range 8-72 months). 
Apomorphine administration 
The patients were admitted to hospital to monitor 
the pattern of on-off fluctuations and for assessment 
of apomorphine responsiveness. All patients were 
TABLE 1. Neuropsychiatric complications pre and post-apomorphine treatment in 12 patients with idiopathic Parkinson’s disease 
rt Age Sex Duration Handy Neuropsychiatric complications 
of I’D 
(years) 
Pre-apomorphine Post-auomorohine 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
64 m 4 
70 f 15 
73 f 18 
39 m 23 
43 m 8 4 
46 m 5 
56 m 15 4 visual hallucinations, anxiety, depression 
50 m 3 
46 f 8 4 
67 f 10 4 
74 m 12 4 
78 m 10 3 
4 
3 
confusion 
complex visual hallucinations 
visual hallucinations, disorientated 
behavioural problems, inappropriate 
sexuality, confusion, disorientated 
on-off paranoia, nightmares 
visual hallucinations, on-off paranoia, 
mental akathisia 
nightmares, confusion, mental akathisia 
paranoid delusions, visual hallucinations, 
aggression 
visual hallucinations 
psychosis, complex visual hallucinations 
visual hallucinations, inappropriate speech 
nil 
nil, apomorphine stopped due to increased falls 
nil 
nil 
nil, apomorphine stopped due to persistent 
nausea 
visual hallucinations reduced but persistent, 
mental akathisia returned on very high doses 
apo, responded to reducing dose 
initial confusion after starting apomorphine, 
responded to reducing Sinemet 
no confusion, mental akathisia and nightmares 
improved 
nil 
nil 
occasional nocturnal confusion only 
no hallucinations, occasional inappropriate 
speech 
USE OF APOMORPHINE IN PARKINSONIAN PATIENTS 105 
TABLE 2. Anti-Parkinsonian treatment before and after stabilisation on apomorphine in 12 subjects with idiopathic Parkinson’s disease 
Patient Anti-Parkinsonian treatment pre-apomorphine therapy Total anti-Parkinsonian treatment when established on 
apomorphine 
8 800 mg 
9 350 mg 
10 400 mg 
11 200 mg 
12 500 mg 
Total daily 
levodopa 
Dopamine 
agonist 
Other Apomorphine total mg 
per day 
Total daily 
levodopa 
Other 
200 mg 
200 mg 
800 mg 
1800 mg 
900 mg 
1000 mg 
1300 mg 
pergolide 
pergolide 
pergolide 
_ 
pergolide 
bromocriptine 
pergolide 
bromocriptine 
bromocriptine 
bromocriptine 
amantadine 
selegiline 
selegiline 
selegiline 
amantadine 
benzhexol 
amantadine 
benzhexol 
selegiline 
amantadine 
100 mg over 12 h 
60 mg over 10 h 
Penject 25 mg 
Penject 60 mg 
Penject 10 mg 
Penject 25 mg 
114 mg over 24 h plus 
penject 8 mg 
36 mg over 12 h 
36 mg over 12 h 
40 mg over 12 h 
36mgover12h 
30mgover 10h 
200 mg 
200 mg amantadine 
300 mg 
1250 mg riserpidone 
800 mg 
1100 mg 
900 mg amantadine 
800 mg 
300 mg 
150 mg 
600 mg 
pre-treated with the peripheral dopamine antagonist, 
domperidone, for three days to prevent nausea. Oral 
dopamine agonists were stopped in all patients prior 
to treatment (mean 7 days, range 3-21 days) with 
apomorphine. Apomorphine was then administered 
by subcutaneous injection to the anterior abdominal 
wall at a dose of 1 mg, increasing by 1 mg increments 
every 20 min until a maximum dose of 10 mg or a 
clinical effect (greater than 50% improvement in motor 
activity scores using a standard apomorphine and 
levodopa challenge protocol) was obtained. This 
threshold determined the dosage used for the sub- 
sequent treatment, delivered either as a continual 
infusion using a Graseby pump over a 12 h period in 
the day or by a ‘Penject’ system. The rate was 
increased in the infusion pump until the optimal 
daily dose was achieved (mean + SD 56.5 ? 32.6 mg), 
and patients were instructed on how to give additional 
boluses if they felt the fixed rate delivery was 
inadequate. The ‘Penject’ system was used when 
patients were able to predict off periods, injections 
being self-administered to the anterior abdominal wall 
(mean -+ SD 25.6 t 20.8 mg). All patients were 
specifically questioned and observed for neuro- 
psychiatric side effects and underwent post apo- 
moprhine neuropschometry and UPDRS assessments 
between 3-6 months after commencing apomorphine. 
The development of erythematous nodules at the 
injection site, a recognised complication of sub- 
cutaneous apomorphine, was reduced by changing 
the needle insertion site every second day for the 
infusion pump delivery system and paying careful 
attention to cleanliness when placing the needle 
subcutaneously. No patient needed to discontinue 
the therapy because of this complication. 
Apomorphine failures 
Two patients discontinued apomorphine: one had 
continued nausea despite concomitant treatment with 
domperidone; one reported an increase in the number 
of falls possibly exacerbated by the increase in 
mobility on apomorphine. 
RESULTS OF SUBJECTS TOLERANT OF, AND 
ESTABLISHED ON, APOMORPHINE 
The results are shown in Table 1. When stabilised 
on subcutaneous apomorphine (mean dose 5 SD: 
48.5 + 33.2 mg/24 h, range 25-124), there was an 
abolition or reduction of neuropsychiatric compli- 
cations and a significant improvement in off periods 
( > 60% reduction in off periods) in all patients. Mean 
Hoehn and Yahr staging improved from 4 to 2.5 and 
two patients reported being able to walk outdoors and 
do shopping for the first time in 4 y. The mean L-dopa 
dosage could be reduced by 20% (mean + SD 566.7 -+ 
392 mg). Three subjects required additional oral 
dopamine agonist therapy without recrudescence of 
neuropsychiatric complications. No new neuropsy- 
chiatric symptoms were observed while patients were 
on apomorphine. One patient reported night time 
confusion but had experienced psychosis and visual 
hallucinations throughout the day on oral therapy. 
One patient intolerant to L-dopa due to the develop- 
ment of severe paranoid delusions is now controlled 
on apomorphine only. One patient increased his 
apomorphine to 140 mg over 24 h and developed 
mental akathisia, which he described as feeling his 
thoughts ‘racing around inside my head’. He has been 
converted to Penjects which at a dose of 20-30 mg per 
day are able to control his severe off periods without 
neuropsychiatric complications. Patient 4 with juve- 
nile onset Parkinson’s Disease has now developed 
signs of sphincter incontinence and some cognitive 
impairment. He still remains sensitive to apomoprhine 
and continues in apomorphine although Risperidone, 
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an atypical neuroleptic has been added (24 months 
after treatment with apomorphine was started) to 
control his mental symptoms. 
DISCUSSION 
Our preliminary observations suggest that patients 
on oral treatment complicated by neuropsychiatric 
side effects may benefit from apomorphine with a 
reduction in these side effects and in the motor 
response fluctuations. Apomorphine has been usefully 
administered to mental patients for more than ninety 
years since Douglas reported its efficacy as a sedative 
in 1907 [9]. Corsini and colleagues in 1981 reported 
marked improvements in psychosis in schizophrenics 
given apomorphine in open and double blind trials [3]. 
Furthermore, Corsini noted that those patients with 
thought disorder, multiple delusions and hallucina- 
tions were most helped by apomorphine administra- 
tion. Whether the reduction in neuropsychiatric side 
effects in Parkinson’s disease patients on sub- 
cutaneous apomorphine is related to the potential 
anti-psychotic action of apomorphine remains 
speculative and controversial. Although our study 
and a previous study by Stibe et al. [l] suggest that 
apomorphine treatment causes less neuropsychiatric 
side effects in PD, yet Ruggieri and colleagues 
reported severe mental confusion and hallucinations 
in patients treated with L-dopa and apomorphine, 
although the patients enrolled in this study had all 
been pre-treated with lisuride, a compound well- 
known to cause severe mental side effects [lo]. 
In our study, all patients who tolerated apo- 
morphine reported a reduction or a complete lack of 
neuropsychiatric side effects. In addition, apo- 
morphine significantly improved the Parkinsonian 
control and the activities of daily living parameters. 
This approach has avoided the concomitant use of 
newer neuroleptics, such as risperidone or clozapine, 
which have significant side effects and are reported to 
have little effect on motor symptoms. Three patients 
who could not tolerate oral dopamine agonists prior to 
apomoprhine, could do so following apomoprhine 
therapy without any significant neuropsychiatric 
complications. Furthermore, one patient remains on 
apomoprhine alone (72 months at the time of writing), 
having been unable to tolerate Ievodopa or oral 
dopamine agonists due to severe psychosis and 
hallucinations. 
We thus believe from our observations that patients 
with IPD, intolerant to oral therapy because of 
neuropsychiatric complications, should be given a 
trial of apomorphine infusion as this may improve 
their Parkinsonian state and neuropsychiatric 
symptoms. 
The mechanism remains uncertain, but may be 
due to a reduction in concomitant oral therapy, 
reduction in off periods or a psychotropic action of 
apomorphine, possibly due to the effect on different 
dopamine receptor subtypes or to an anti-psychotic 
action of the piperidine moiety of apomorphine. In this 
study, apomorphine was tolerated by one subject who 
was intolerant to L-dopa and to oral dopamine 
agonists because of severe agitation and psychosis. 
This supports our observation that apomorphine may 
indeed have a psychotropic action of its own, although 
this may well be clinically insiginificant because of the 
almost invariable concomitant reduction in levodopa 
or oral dopamine agonist doseage after apomorphine 
is commenced. However, our single patient on 
apomorphine therapy alone provides further support 
of our hypothesis, as does the fact that three patients 
could tolerate oral dopamine agonists while on 
apomorphine only. DuP734, a piperidine analogue, is 
known to have anti-psychotic actions, and is a 
selective and potent sigma and 5HT2 receptor ligand 
with weak D2 affinity [II]. In mice models, DuP734 
has little anti-apomorphine effect as measured by its 
ability to block apomorphine induced climbing [12]. 
The combination of piperidine and apomorphine 
would therefore not be antagonistic and may thus 
lead to differential actions on the psyche and motor 
responses. 
The observations from this open study need to be 
investigated further with a double blind, placebo 
controlled study to further examine the role of 
apomorphine in the treatment of Parkinson’s Disease 
patients with drug induced neuropsychiatric 
complications. 
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